Is your active pharmaceutical ingredient ready for good manufacturing practice scale up?

Log in to watch this webinar

Not registered yet? 创建账户

Going beyond candidate nomination

Developing a small molecule active pharmaceutical ingredient (API) is often a risky process. Reaching the goal, be it first in human studies or commercial manufacture, requires data and material without incurring unnecessary delays or impact on costs. Therefore, it’s important to start thinking about process steps and scalability early.

During this webinar, you will learn:

  • how to assess your process, from safety to efficiency and robustness, as well as understanding the solid form
  • the importance of having strong analytical methods to detect impurities and understand their impact, and what supporting analytical data is required prior to good manufacturing practice (GMP) manufacture which makes part of investigational new drug/investigational medicinal product dossier (IND/IMPD) filing 

You will also learn how Concept Life Sciences CRO services can support you in progressing your drug development journey from route design to process development, ensuring readiness for GMP manufacture.


  • David Fengas - Director of CMC Services - Concept Life Sciences and 
  • Caroline German - Technical Director - Concept Life Sciences


Who should attend? 

  • Anyone interested in material characterization to support process development 
  • Anyone who is ready to take their API candidate into early development 
  • Anyone who is interested in finding out the IND submission requirements
  • Anyone who is interested in finding out more about route design, process development and phase appropriate scale up 

What will you learn? 

  • When to look at route design 
  • SELECT criteria 
  • Method development and validation 
  • keys to process robustness  detecting your impurities 
  • How to be GMP ready 
  • importance of data in regulatory submission